Understanding Adult SMA Diagnosis & Treatment Experiences
Part of Brain & nervous system clinical trials.
This trial explores the experiences of adults with spinal muscular atrophy (SMA) in the MedStar Health System, looking at how they are diagnosed and treated, and any differences in care they may face.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of spinal muscular atrophy (SMA).
- You must be 18 years old or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study talks with parents about their feelings and experiences after their baby's newborn screening for spinal muscular atrophy (SMA), a rare genetic condition. It aims to understand how parents cope with the results, which can help improve support for families.
This study creates a registry and clinical hub for adults with 5q spinal muscular atrophy (SMA). It aims to track health outcomes and improve care for people living with SMA.
This trial tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) is safe and tolerable for people with spinal muscular atrophy (SMA). It may help improve muscle function by activating low motor neurons.
This study looks at changes in two genes, SMN1 and SMN2, which are linked to spinal muscular atrophy (SMA). It aims to better understand the different versions of these genes in healthy people and those with SMA. Participating involves a blood sample and genetic analysis.
This trial tests a new medicine called EXG001-307 for babies with spinal muscular atrophy (SMA) types 1 and 2. The goal is to see if it is safe and helps with muscle strength and breathing.
This study uses wearable devices (like smartwatches or activity trackers) to monitor movement and motor development in young children with spinal muscular atrophy (SMA), a rare genetic condition affecting muscle strength. The goal is to see if wearables can track disease progression and treatment response better than traditional clinic visits.
Hear when a new Spinal Muscular Atrophy (SMA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.